{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:15:08Z","timestamp":1776287708267,"version":"3.50.1"},"reference-count":8,"publisher":"American Scientific Publishers","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["j nanosci nanotechnol"],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:p>The essence of sepsis is the excessive immune response caused by infectious factors, which leads to the release of a large number of inflammatory factors and the injury of tissues and organs. Once the reaction is triggered, it will develop according to its own rules, and it does not\n depend on infection factors. The occurrence and severity of sepsis depend entirely on the reaction of the body. When pathogens invade the body, they rely on pattern recognition receptors to play a defensive role, TLR4 is the main switch of innate immunity. The current research shows that LPS\n can induce the up-regulation of TLR4 gene expression in monocytes, neutrophils and other immune cells. The upregulated TLR4, as a new receptor, mediates more cell activation and the release of inflammatory mediators. Under this positive feedback, the inflammatory response is constantly amplified,\n which eventually leads to the development of sepsis. In this study, TLR4 extracellular domain antigen was obtained by protein expression and purification, and anti-TLR4 C-terminal and intermediate domain nano-antibody was obtained by phage display antibody library preparation technology. <jats:italic>In\n vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> experiments confirmed that anti-TLR4 nano-antibody can effectively reduce the release of inflammatory factors and improve the survival rate of animals, while the C-terminal and intermediate domain are closed at the same time, the effect is more obvious. The clinical\n treatment of sepsis provides new ideas and strategies.<\/jats:p>","DOI":"10.1166\/jnn.2021.18664","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T04:53:47Z","timestamp":1605243227000},"page":"1048-1053","source":"Crossref","is-referenced-by-count":11,"title":["Preparation of Anti Toll-Like Receptor-4 Nano-Antibody and Its Effect on Gram Negative Sepsis"],"prefix":"10.1166","volume":"21","author":[{"given":"Shu","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Intensive Care Unit, The 2nd Affiliated Hospital of Chengdu Medical College Nuclear Industry 416 Hospital, Chengdu, 610000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Emergency, The 2nd Affiliated Hospital of Chengdu Medical College Nuclear Industry 416 Hospital, Chengdu, 610000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Emergency, The 2nd Affiliated Hospital of Chengdu Medical College Nuclear Industry 416 Hospital, Chengdu, 610000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17","reference":[{"issue":"(12)","key":"r1","first-page":"pp.1723","article-title":"Advances in research on relationship between Toll-like receptor 4 and sepsis.","volume":"25","author":"Liu","year":"2012","journal-title":"Chinese Journal of Biologi-cals"},{"issue":"(12)","key":"r2","first-page":"pp.1373","article-title":"Recognition of lipopolysaccharide pattern by TLR4 complexes.","volume":"45","author":"Park","year":"2012","journal-title":"Experimental & Molecular Medicine"},{"issue":"(2)","key":"r3","first-page":"pp.67","article-title":"Clinical value of immune function monitoring in patients with sepsis.","volume":"32","author":"Yao","year":"2016","journal-title":"Miscellaneous Burn in China"},{"issue":"(5)","key":"r4","doi-asserted-by":"crossref","first-page":"pp.906","DOI":"10.1016\/j.cell.2007.08.002","article-title":"Crystal structure of the TLR4-MD-2 complex with boundendotoxin antagonist Eritoran.","volume":"130","author":"Kim","year":"2007","journal-title":"Cell"},{"issue":"(6)","key":"r5","doi-asserted-by":"crossref","first-page":"pp.4319","DOI":"10.1021\/nn1023363","article-title":"Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy.","volume":"5","author":"Vande","year":"2011","journal-title":"ACS Nano"},{"issue":"(12)","key":"r6","first-page":"pp.2645","article-title":"Nanobodies\u2014The new concept in antibody engineering.","volume":"8","author":"Effar","year":"2009","journal-title":"African Journal of Biotechnology"},{"issue":"(7)","key":"r7","doi-asserted-by":"crossref","first-page":"pp.549","DOI":"10.1093\/protein\/gzq028","article-title":"Stability engineering of scFvs for the development of bispecific and multivalent antibodies.","volume":"23","author":"Miller","year":"2010","journal-title":"Protein Eng. Des. Sel."},{"issue":"(7)","key":"r8","first-page":"pp.655","article-title":"Preparation of monoclonal antibody against extracellular C-terminal domain of Toll-like receptor 4 and its preliminary effect in the treatment of sepsis.","volume":"32","author":"Chen","year":"2016","journal-title":"Chinese Journal of Trauma"}],"container-title":["Journal of Nanoscience and Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/asp\/jnn\/2021\/00000021\/00000002\/art00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T04:48:39Z","timestamp":1608785319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.1166\/jnn.2021.18664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"alternative-id":["1533-4880(20210201)21:2L.1048;1-"],"URL":"https:\/\/doi.org\/10.1166\/jnn.2021.18664","relation":{},"ISSN":["1533-4880"],"issn-type":[{"value":"1533-4880","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}